Explore STVN stock analysis with latest price trends, earnings data, technical indicators, and analyst forecasts. Is STVN stock a buy in 2026? Get insights on valuation and outlook.
Introduction
Stevanato Group S.p.A. (STVN) designs and supplies glass containers, syringes, and systems for biopharma and healthcare firms. Investors watch STVN stock closely now due to recent Q4 2025 earnings misses and biopharma sector volatility. Broader market pressures from high interest rates hit healthcare stocks, yet biotech demand offers upside.
STVN stock price reflects this mix. The company beat revenue estimates but saw shares drop amid growth worries.
Latest Stock Price & Trend
As of last market close on March 4, 2026, STVN stock price stands at $16.23. It fell 15.29% over the past month, signaling short-term weakness.
The 1-day performance showed minor gains, but 5-day and 1-month trends point bearish at -20.71% yearly decline. Over 3 months, shares lost ground amid earnings volatility; 6-month and year-to-date trends mirror this, down from peaks.
The 52-week high hit €28.00, low at €13.91, with current price near the bottom. This bearish trend warns investors of caution, as momentum fades without catalysts.
Technical Analysis
Support levels sit near $15.00, where buyers may step in to halt falls. Resistance looms at $18.92 (50-day MA), blocking upside.
RSI reading hovers around 35, indicating oversold conditions that could spark a rebound. MACD shows bearish crossover, confirming downtrend momentum.
The 50-day MA at €18.92 tops the 200-day at €22.31, no golden cross in sight—death cross lingers. Trading volume rose on down days, suggesting strong selling pressure.
These signals matter as they help spot entry points; oversold RSI hints at relief, but MACD urges patience.
Analyst Ratings & Price Targets
Five analysts rate STVN stock Moderate Buy: 1 Buy, 3 Hold, 1 Sell. Average price target hits $27.81, with highs near $30 and lows at $20—84% upside potential.
Recent holds from firms like Conestoga Capital cite volatility. No major upgrades lately.
This sentiment means pros see value long-term but expect near-term bumps, guiding everyday investors wisely.
Insider Activity
Limited recent insider buying; small sales noted in Q4 2025 filings. No large transactions stand out per SEC data.
Management holds steady, implying neutral confidence amid market dips. This lacks strong bullish signals but shows no panic selling.
Valuation Analysis
Trailing P/E ratio clocks at 28.04, forward P/E lower on growth hopes. Price-to-sales remains moderate versus peers like Corning.
Revenue grew to $352.68M last quarter, beating $346.26M estimates; YoY EPS up modestly. Net margin at 11.73%, ROE 10.34%, with solid free cash flow.
Debt low, cash healthy, better than Zoom’s multiples but trails Microsoft scale. STVN stock appears fairly valued, not screaming undervalued yet.
Recent Earnings & Catalysts
Q4 2025 EPS hit $0.20, matching estimates; revenue topped at $352.68M. Shares dipped post-earnings on guidance caution.
Upcoming March 6, 2026, results test high-value shift. Catalysts include biopharma partnerships and vial demand.
Earnings drove 15% monthly drop, highlighting execution risks.
Bullish Case
Biopharma demand fuels revenue growth via glass tech edge. High-value products promise margins.
Operational tweaks cut costs; market expansion aids. Steady 10%+ ROE supports compounding.
Bearish Case
Competition from West pharma squeezes shares. Growth slowed yearly at -20.71%.
Margin pressures and economic slowdowns loom. Regulatory hurdles in biotech add caution.
Market Sentiment & Investor Psychology
Short interest low, under 5%. Options lean calls slightly over puts.
Institutions hold steady; retail chases dips. Sentiment neutral, value bias over momentum.
Short-Term Outlook
Oversold RSI and volume spikes suggest bounce potential. Earnings on March 6 could swing it.
Watch support at $15; bearish MACD caps gains without volume shift. Expect sideways chop.
Medium to Long-Term Outlook
Strong biopharma model and financials position well. Industry growth offsets rivals.
Hold for now; accumulate on dips if earnings deliver. Long-term watchlist worthy.
FAQ Section
Is STVN stock a buy right now?
Moderate Buy rating, but wait for earnings stability.
What is the price target for STVN stock?
Average $27.81, up to $30 from analysts.
What are major risks for STVN stock?
Slow growth, competition, margin squeezes.
What is STVN earnings outlook?
Q1 2026 tests revenue beats; EPS steady.
STVN stock forecast long-term?
Positive if biopharma demand holds.
Suggestions
- Compare with Opendoor stock analysis
- See our Microsoft stock forecast
- Read our tech sector valuation breakdown
Final Balanced Conclusion
Hold STVN stock for now. Analyst targets offer upside, but trends and risks warrant caution until earnings clarity. Watchlist it.
Disclaimer: This article is for informational purposes only and not financial advice.